APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Canine Tumor Screening

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Canine Tumor Screening Market Outlook and Growth Opportunities 2026

30 January 2026194 pages

Choose your research edition.

Industry ResearchCanine Tumor Screening Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Canine Tumor Screening Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Canine Tumor Screening Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Canine Tumor Screening Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Canine Tumor Screening Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Canine Tumor Screening market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Canine Tumor Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Canine Tumor Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Canine Tumor Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Canine Tumor Screening market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Canine Tumor Screening market include PetDx, CYTOGEN, BioChain, Small Door, ANGLE, BioChain Institute Inc. and CANCAN DIAGNOSTICS., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Canine Tumor Screening market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Canine Tumor Screening and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Canine Tumor Screening revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Canine Tumor Screening market.

Canine Tumor Screening Segment by Company

PetDx

CYTOGEN

BioChain

Small Door

ANGLE

BioChain Institute Inc.

CANCAN DIAGNOSTICS.

Canine Tumor Screening Segment by Type

Cut Biopsy

Needle Biopsy

Canine Tumor Screening Segment by Application

Pet Hospital

Clinic

Canine Tumor Screening Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Canine Tumor Screening status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Canine Tumor Screening key companies, revenue, market share, and recent developments.

3. To split the Canine Tumor Screening breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Canine Tumor Screening market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Canine Tumor Screening significant trends, drivers, influence factors in global and regions.

6. To analyze Canine Tumor Screening competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Canine Tumor Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Canine Tumor Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Canine Tumor Screening.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Canine Tumor Screening industry.

Chapter 3: Detailed analysis of Canine Tumor Screening company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Canine Tumor Screening in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Canine Tumor Screening in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Canine Tumor Screening Industry Trends Table 2. Canine Tumor Screening Industry Drivers Table 3. Canine Tumor Screening Industry Opportunities and Challenges Table 4. Canine Tumor Screening Industry Restraints Table 5. Global Canine Tumor Screening Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Canine Tumor Screening Revenue Share by Company (2021-2026) Table 7. Global Canine Tumor Screening Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Canine Tumor Screening Key Company Manufacturing Base & Headquarters Table 9. Global Canine Tumor Screening Company, Product Type & Application Table 10. Global Canine Tumor Screening Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Canine Tumor Screening by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cut Biopsy Table 15. Significant Companies of Needle Biopsy Table 16. Global Canine Tumor Screening Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Canine Tumor Screening Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Canine Tumor Screening Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Canine Tumor Screening Sales Value Share by Type (2021-2026) Table 20. Global Canine Tumor Screening Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Pet Hospital Table 22. Significant Companies of Clinic Table 23. Global Canine Tumor Screening Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Canine Tumor Screening Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Canine Tumor Screening Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Canine Tumor Screening Sales Value Share by Application (2021-2026) Table 27. Global Canine Tumor Screening Sales Value Share by Application (2027-2032) Table 28. Global Canine Tumor Screening Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Canine Tumor Screening Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Canine Tumor Screening Sales Value Share by Region (2021-2026) Table 31. Global Canine Tumor Screening Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Canine Tumor Screening Sales Value Share by Region (2027-2032) Table 33. Global Canine Tumor Screening Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Canine Tumor Screening Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Canine Tumor Screening Sales Value Market Share by Country (2021-2026) Table 36. Global Canine Tumor Screening Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Canine Tumor Screening Sales Value Market Share by Country (2027-2032) Table 38. PetDx Company Information Table 39. PetDx Business Overview Table 40. PetDx Canine Tumor Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. PetDx Canine Tumor Screening Product Portfolio Table 42. PetDx Recent Development Table 43. CYTOGEN Company Information Table 44. CYTOGEN Business Overview Table 45. CYTOGEN Canine Tumor Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. CYTOGEN Canine Tumor Screening Product Portfolio Table 47. CYTOGEN Recent Development Table 48. BioChain Company Information Table 49. BioChain Business Overview Table 50. BioChain Canine Tumor Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. BioChain Canine Tumor Screening Product Portfolio Table 52. BioChain Recent Development Table 53. Small Door Company Information Table 54. Small Door Business Overview Table 55. Small Door Canine Tumor Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Small Door Canine Tumor Screening Product Portfolio Table 57. Small Door Recent Development Table 58. ANGLE Company Information Table 59. ANGLE Business Overview Table 60. ANGLE Canine Tumor Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. ANGLE Canine Tumor Screening Product Portfolio Table 62. ANGLE Recent Development Table 63. BioChain Institute Inc. Company Information Table 64. BioChain Institute Inc. Business Overview Table 65. BioChain Institute Inc. Canine Tumor Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. BioChain Institute Inc. Canine Tumor Screening Product Portfolio Table 67. BioChain Institute Inc. Recent Development Table 68. CANCAN DIAGNOSTICS. Company Information Table 69. CANCAN DIAGNOSTICS. Business Overview Table 70. CANCAN DIAGNOSTICS. Canine Tumor Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. CANCAN DIAGNOSTICS. Canine Tumor Screening Product Portfolio Table 72. CANCAN DIAGNOSTICS. Recent Development Table 73. Research Programs/Design for This Report Table 74. Authors List of This Report Table 75. Secondary Sources Table 76. Primary Sources List of Figures Figure 1. Canine Tumor Screening Product Image Figure 2. Global Canine Tumor Screening Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Canine Tumor Screening Market Size (2021-2032) & (US$ Million) Figure 4. Global Canine Tumor Screening Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cut Biopsy Image Figure 8. Needle Biopsy Image Figure 9. Global Canine Tumor Screening Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Canine Tumor Screening Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Canine Tumor Screening Sales Value Share by Type (2021-2032) Figure 12. Pet Hospital Image Figure 13. Clinic Image Figure 14. Global Canine Tumor Screening Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Canine Tumor Screening Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Canine Tumor Screening Sales Value Share by Application (2021-2032) Figure 17. Global Canine Tumor Screening Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Canine Tumor Screening Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Canine Tumor Screening Sales Value (2021-2032) & (US$ Million) Figure 20. North America Canine Tumor Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Canine Tumor Screening Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Canine Tumor Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Canine Tumor Screening Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Canine Tumor Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Canine Tumor Screening Sales Value (2021-2032) & (US$ Million) Figure 26. South America Canine Tumor Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Canine Tumor Screening Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Canine Tumor Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Canine Tumor Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Cut Biopsy
  • Needle Biopsy
Applications
  • Pet Hospital
  • Clinic
Companies covered
  • PetDx
  • CYTOGEN
  • BioChain
  • Small Door
  • ANGLE
  • BioChain Institute Inc.
  • CANCAN DIAGNOSTICS.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Canine Tumor Screening Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Canine Tumor Screening Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Canine Tumor Screening Market Dynamics
  1. 2.1 Canine Tumor Screening Industry Trends
  2. 2.2 Canine Tumor Screening Industry Drivers
  3. 2.3 Canine Tumor Screening Industry Opportunities and Challenges
  4. 2.4 Canine Tumor Screening Industry Restraints
3 Canine Tumor Screening Market by Company
  1. 3.1 Global Canine Tumor Screening Company Revenue Ranking in 2025
  2. 3.2 Global Canine Tumor Screening Revenue by Company (2021-2026)
  3. 3.3 Global Canine Tumor Screening Company Ranking (2024-2026)
  4. 3.4 Global Canine Tumor Screening Company Manufacturing Base and Headquarters
  5. 3.5 Global Canine Tumor Screening Company Product Type and Application
  6. 3.6 Global Canine Tumor Screening Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Canine Tumor Screening Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Canine Tumor Screening Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Canine Tumor Screening Market by Type
  1. 4.1 Canine Tumor Screening Type Introduction
  2. 4.1.1 Cut Biopsy
  3. 4.1.2 Needle Biopsy
  4. 4.2 Global Canine Tumor Screening Sales Value by Type
  5. 4.2.1 Global Canine Tumor Screening Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Canine Tumor Screening Sales Value by Type (2021-2032)
  7. 4.2.3 Global Canine Tumor Screening Sales Value Share by Type (2021-2032)
5 Canine Tumor Screening Market by Application
  1. 5.1 Canine Tumor Screening Application Introduction
  2. 5.1.1 Pet Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Canine Tumor Screening Sales Value by Application
  5. 5.2.1 Global Canine Tumor Screening Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Canine Tumor Screening Sales Value by Application (2021-2032)
  7. 5.2.3 Global Canine Tumor Screening Sales Value Share by Application (2021-2032)
6 Canine Tumor Screening Regional Value Analysis
  1. 6.1 Global Canine Tumor Screening Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Canine Tumor Screening Sales Value by Region (2021-2032)
  3. 6.2.1 Global Canine Tumor Screening Sales Value by Region: 2021-2026
  4. 6.2.2 Global Canine Tumor Screening Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Canine Tumor Screening Sales Value (2021-2032)
  7. 6.3.2 North America Canine Tumor Screening Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Canine Tumor Screening Sales Value (2021-2032)
  10. 6.4.2 Europe Canine Tumor Screening Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Canine Tumor Screening Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Canine Tumor Screening Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Canine Tumor Screening Sales Value (2021-2032)
  16. 6.6.2 South America Canine Tumor Screening Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Canine Tumor Screening Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Canine Tumor Screening Sales Value Share by Country, 2025 VS 2032
7 Canine Tumor Screening Country-level Value Analysis
  1. 7.1 Global Canine Tumor Screening Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Canine Tumor Screening Sales Value by Country (2021-2032)
  3. 7.2.1 Global Canine Tumor Screening Sales Value by Country (2021-2026)
  4. 7.2.2 Global Canine Tumor Screening Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Canine Tumor Screening Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Canine Tumor Screening Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Canine Tumor Screening Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 PetDx
  2. 8.1.1 PetDx Company Information
  3. 8.1.2 PetDx Business Overview
  4. 8.1.3 PetDx Canine Tumor Screening Revenue and Gross Margin (2021-2026)
  5. 8.1.4 PetDx Canine Tumor Screening Product Portfolio
  6. 8.1.5 PetDx Recent Developments
  7. 8.2 CYTOGEN
  8. 8.2.1 CYTOGEN Company Information
  9. 8.2.2 CYTOGEN Business Overview
  10. 8.2.3 CYTOGEN Canine Tumor Screening Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CYTOGEN Canine Tumor Screening Product Portfolio
  12. 8.2.5 CYTOGEN Recent Developments
  13. 8.3 BioChain
  14. 8.3.1 BioChain Company Information
  15. 8.3.2 BioChain Business Overview
  16. 8.3.3 BioChain Canine Tumor Screening Revenue and Gross Margin (2021-2026)
  17. 8.3.4 BioChain Canine Tumor Screening Product Portfolio
  18. 8.3.5 BioChain Recent Developments
  19. 8.4 Small Door
  20. 8.4.1 Small Door Company Information
  21. 8.4.2 Small Door Business Overview
  22. 8.4.3 Small Door Canine Tumor Screening Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Small Door Canine Tumor Screening Product Portfolio
  24. 8.4.5 Small Door Recent Developments
  25. 8.5 ANGLE
  26. 8.5.1 ANGLE Company Information
  27. 8.5.2 ANGLE Business Overview
  28. 8.5.3 ANGLE Canine Tumor Screening Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ANGLE Canine Tumor Screening Product Portfolio
  30. 8.5.5 ANGLE Recent Developments
  31. 8.6 BioChain Institute Inc.
  32. 8.6.1 BioChain Institute Inc. Company Information
  33. 8.6.2 BioChain Institute Inc. Business Overview
  34. 8.6.3 BioChain Institute Inc. Canine Tumor Screening Revenue and Gross Margin (2021-2026)
  35. 8.6.4 BioChain Institute Inc. Canine Tumor Screening Product Portfolio
  36. 8.6.5 BioChain Institute Inc. Recent Developments
  37. 8.7 CANCAN DIAGNOSTICS.
  38. 8.7.1 CANCAN DIAGNOSTICS. Company Information
  39. 8.7.2 CANCAN DIAGNOSTICS. Business Overview
  40. 8.7.3 CANCAN DIAGNOSTICS. Canine Tumor Screening Revenue and Gross Margin (2021-2026)
  41. 8.7.4 CANCAN DIAGNOSTICS. Canine Tumor Screening Product Portfolio
  42. 8.7.5 CANCAN DIAGNOSTICS. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst